Weekly Recap | TMO.US +0.49%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Thermo Fisher (TMO) added 0.49% this week, closing at $658.02 and trailing the S&P 500’s 1.15% gain by roughly 0.66 percentage points. Monday’s session pushed 3.35% higher and carried the stock to an intraday record, then Tuesday opened around 683 and peaked at $694.325 before pulling back. Thursday dipped to $635.32, and Friday recovered to $658.02. The week’s 9.
The Week
Thermo Fisher (TMO) added 0.49% this week, closing at $658.02 and trailing the S&P 500’s 1.15% gain by roughly 0.66 percentage points. Monday’s session pushed 3.35% higher and carried the stock to an intraday record, then Tuesday opened around 683 and peaked at $694.325 before pulling back. Thursday dipped to $635.32, and Friday recovered to $658.02. The week’s 9.11% range was wide, with turnover roughly 15% above recent median daily volume, leaving prices in a high-level consolidation.
Key Events
JPMorgan put Thermo Fisher on its October stock picks list early in the week, directing attention to its exposure across health care and AI power infrastructure. On Tuesday the shares touched a record high, while the company showcased new drug-development solutions at the CPHI Milan 2026 event and took part in the launch of the Digital CMC Consortium. Midweek brought two sessions of relative weakness, but several brokers raised 12-month price targets, first to $678.17 and then to $682.12, implying 2% to 5% upside. The dominant thread was resilient demand for life-science tools alongside industry innovation, against choppy price action at the highs.
Analyst Ratings
Across 29 institutions covering the stock, 19 rate it buy, 4 overweight, 3 hold, 1 underweight, and 2 have no opinion; no firm has a sell. The consensus rating stands at strong buy, with a consensus target of $677.24, about 2.9% above the latest close. Individual targets range from $560 to $800, a wide spread. Within the life-science tools and services industry, Thermo Fisher ranks first among 54 companies for its rating profile.
The Week Ahead
Tuesday brings the NFIB small-business optimism index and existing-home sales data; Wednesday’s US CPI and core CPI prints will shape rate and inflation expectations over the next sessions. Thermo Fisher reports third-quarter fiscal 2026 results before the open on 21 October, with consensus EPS near $5.03 on roughly $12bn in revenue. The key test is whether the quarter supports this week’s innovation narrative and valuation level.
In Short
This week combined a high-level, high-volume range with a strongly positive broker picture and a top industry-ranking profile. That sits against a P/E around 34.9x and a P/B near 4.62x, while the latest session’s money flow showed net buying in small and medium lots but net selling in large lots. The tension ahead is whether elevated valuation and positive ratings can be validated by third-quarter results, and how the inflation data reshapes risk appetite in the meantime.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.